Publications by authors named "F Sedda"
Objective: Non-alcoholic fatty liver disease (NAFLD), the primary hepatic consequence of obesity, is affecting about 25% of the global adult population. The aim of this study was to examine the in vivo role of STE20-type protein kinase TAOK3, which has been previously reported to regulate hepatocellular lipotoxicity in vitro, in the development of NAFLD and systemic insulin resistance in the context of obesity.
Methods: Taok3 knockout mice and wild-type littermates were challenged with a high-fat diet.
Article Synopsis
- Recent studies indicate that host genetic factors, particularly HLA-G molecules, may play a significant role in determining the severity of COVID-19 effects among individuals.
- The study compared immune-genetic characteristics of 381 COVID-19 patients and 420 healthy controls from Sardinia, revealing that certain gene polymorphisms are associated with varying disease severity.
- Key findings included a more common extended haplotype in patients with mild symptoms and protective effects from other genetic factors, while the Neanderthal gene variant showed negative implications for disease progression.
Article Synopsis
- The study explores how targeting the thyroid hormone receptor (THRβ) with a new drug called TG68 can help reduce liver fat accumulation and cancer risk in rats with non-alcoholic fatty liver disease (NAFLD).
- Experiments showed that TG68 significantly lowered liver weight, fat, cholesterol, and blood sugar levels while also reversing early signs of liver cancer in the rats.
- Unlike another drug, Resmetirom, which only reduced liver fat, TG68 also demonstrated potential anti-cancer effects, highlighting its promise as a treatment for NAFLD-related liver issues.
Unlabelled: In several countries, thrombotic events after vaccination with ChAdOx1 nCoV-19 have led to heterologous messenger RNA (mRNA) boosting. We tested the antibody response to SARS-CoV-2 spike protein four weeks after heterologous priming with the ChAdOx1 (ChAd) vector vaccine followed by boosting with BNT162b2(ChAd/BNT), comparing data of homologous regimen (BNT/BNT, ChAd/ChAd) subjects positive for SARS-CoV-2 after the first dose of BNT162b2 (BNT1dose/CoV2) and convalescent COVID-19.
Methods: healthy subjects naïve for SARS-CoV-2 infection were assessed for serum IgG anti-S-RBD response 21 days after priming (T1), 4 (T) and 15 (T) weeks after booster dose.
SARS-CoV-2 vaccination with mRNA product BNT162b2 elicited high immunogenicity in healthy subjects in trials. This study aims to better understand the factors that influence the humoral immune response to vaccination against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs). We enrolled patients and healthy healthcare workers control group (HCW) that underwent mRNA BNT162b2 vaccination and measured the serum IgG anti-S-RBD response at booster dose (T1), one month after booster dose (T2) and up to 5 months (T3).
View Article and Find Full Text PDF